Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pemlimogene merolisbac
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Pemlimogene merolisbac is a recombinant live attenuated double-deleted (LADD) strain of *Listeria monocytogenes* engineered to express a fusion protein containing tumor-associated antigens, including mesothelin and EGFRvIII. It functions as an immunotherapy and cancer vaccine by activating the immune system, leading to recruitment and activation of cytotoxic T lymphocytes against tumor cells expressing these antigens. The drug was initially developed by Aduro BioTech and later advanced by Chinook Therapeutics (now part of Novartis), Janssen Biotech, and Bristol Myers Squibb. Its primary indication has been non-small cell lung cancer, with additional investigation in ovarian cancer[2][3][4][5].
- Other names
- pemlimogene merolisbac
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)Mesothelin
Beyond the preview
Go deeper on Pemlimogene merolisbac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pemlimogene merolisbac.